|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2010-2-22
|
|
pubmed:abstractText |
Antibody-dependent cellular cytotoxicity (ADCC) by natural killer (NK) cells is a major effector mechanism of the monoclonal anti-CD20 antibody rituximab in eliminating B-cell lymphomas. Resistance to this treatment occurs, although CD20 antigen is expressed on the tumor cells.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal...,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD20,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/HLA-C Antigens,
http://linkedlifedata.com/resource/pubmed/chemical/Histocompatibility Antigens Class I,
http://linkedlifedata.com/resource/pubmed/chemical/KIR2DL1 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/KIR2DL2 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/KIR2DL3 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, KIR,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, KIR2DL1,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, KIR2DL2,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, KIR2DL3,
http://linkedlifedata.com/resource/pubmed/chemical/rituximab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1873-2399
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2010 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
38
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
213-21
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:20056126-Antibodies, Monoclonal,
pubmed-meshheading:20056126-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:20056126-Antibody-Dependent Cell Cytotoxicity,
pubmed-meshheading:20056126-Antigens, CD20,
pubmed-meshheading:20056126-Antineoplastic Agents,
pubmed-meshheading:20056126-Cell Line,
pubmed-meshheading:20056126-Cell Line, Tumor,
pubmed-meshheading:20056126-Cells, Cultured,
pubmed-meshheading:20056126-Dose-Response Relationship, Drug,
pubmed-meshheading:20056126-Enzyme-Linked Immunosorbent Assay,
pubmed-meshheading:20056126-Flow Cytometry,
pubmed-meshheading:20056126-HLA-C Antigens,
pubmed-meshheading:20056126-Histocompatibility Antigens Class I,
pubmed-meshheading:20056126-Humans,
pubmed-meshheading:20056126-K562 Cells,
pubmed-meshheading:20056126-Killer Cells, Natural,
pubmed-meshheading:20056126-Lymphocyte Activation,
pubmed-meshheading:20056126-Lymphocytes,
pubmed-meshheading:20056126-Lymphoma, B-Cell,
pubmed-meshheading:20056126-Receptors, KIR,
pubmed-meshheading:20056126-Receptors, KIR2DL1,
pubmed-meshheading:20056126-Receptors, KIR2DL2,
pubmed-meshheading:20056126-Receptors, KIR2DL3
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression.
|
|
pubmed:affiliation |
Department of Haematology and Oncology, Georg-August University of Göttingen, Göttingen, Germany. a.borgerding@med.uni-goettingen.de
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
